Zymeworks posts Q2 net income of $2.3M on revenue of $48.7M; cash runway into 2H-2027

Zymeworks Inc.

2025-Q2 EPS reported -$0.27 revenue$75,836,000

Revenue of $48.7M in Q2 2025 vs $19.2M in Q2 2024, driven by $20M BeOne milestone and $7.5M BMS license option.
Net income of $2.3M compared to net loss of $37.7M in Q2 2024; R&D expenses $34.4M, G&A $15.0M.
Cash resources $333.4M as of June 30, 2025, projected to fund operations into 2H-2027 with anticipated milestones.
FDA cleared IND for ZW251 (GPC3-targeting ADC); Phase 1 planned for 2025, joining ZW171 and ZW191 in clinic.
Jazz reported Ziihera net sales of $5.5M in Q2; conditional EU approval for HER2+ BTC and China approval noted.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.